

## Medicines Update: December 2025

This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.

### New marketing authorisations

#### Novel products

Varenzin 25 mg/ml Oral Suspension for Cats containing molidustat sodium. This is a new active substance for the treatment of non-regenerative anaemia associated with chronic kidney disease (CKD) in cats.

Table 1 shows the new marketing authorisations for December 2025

TABLE 1: New marketing authorisations in December 2025

<b>New Marketing Authorisations</b>			
<b>Product name and target species</b>	<b>Active substance</b>	<b>Authorisation Holder, territory, and distribution category</b>	<b>Therapeutic group</b>
<b>Food Animals</b>			
Lenzelta Suspension for Injection for Cattle	Escherichia coli, Staphylococcus aureus	Boehringer Ingelheim Vetmedica GmbH NI, POM-V	Inactivated Bacterial Vaccine
Lexylan 180 mg/ml Suspension for Injection for Cattle, Dogs and Cats	Cefalexin	Emdoka bvba GB, POM-V	Antimicrobial
Pergocoat 0.25 mg Film-Coated Tablets for Horses	Pergolide mesylate	Alfasan Nederland B.V. NI, POM-V	Neurological Agent
<b>Non-food Animals</b>			
Carpcoat 8 mg /20 mg / 40 mg / 80 mg Film-coated Tablets for Dogs	Carprofen	Alfasan Nederland B.V. NI, POM-V	Anti Inflammatory NSAID
Cartaxx 20 mg / 50 mg / 100 mg Chewable Tablets for Dogs	Carprofen	Alfasan Nederland B.V. NI, POM-V	Anti Inflammatory NSAID
Chanoxidyl 2 mg/ml Solution for Injection for Cats	Meloxicam	C&H Generics Ltd	Anti Inflammatory NSAID

		GB & NI, POM-V	
Dexmedocord 0.5 mg/mL Solution for Injection (cats, Dogs)	Dexmedetomidine Hydrochloride	Accord Healthcare B.V NI, POM-V	Neurological Agent sedative
Meloxaid 2 mg/ml Solution for Injection for Cats	Meloxicam	C&H Generics Ltd GB & NI, POM-V	Anti Inflammatory NSAID
Preglukord 1 mg Tablets for Dogs and Cats Preglukord 5 mg Tablets for Dogs and Cats Preglukord 25 mg Tablets for Dogs	Prednisolone	Accord Healthcare B.V NI, POM-V	Anti Inflammatory corticosteroid
Rheumocam 2 mg/ml Solution for Injection for Cats	Meloxicam	Chanelle Pharmaceuticals Manufacturing Ltd GB, POM-V	Anti Inflammatory NSAID
Robexera 6 mg Chewable Tablets for Cats	Robenacoxib	KRKA, d.d., Novo mesto GB, POM-V	Anti Inflammatory NSAID
Varenzin 25 mg/ml Oral Suspension for Cats	Molidustat sodium	Elanco GmbH GB, POM-V	Miscellaneous

See the VMD's [Product Information Database \(www.gov.uk/check-animal-medicine-licensed\)](http://www.gov.uk/check-animal-medicine-licensed) for more information on each of these products. There may be a delay before formal documentation is available for some Northern Ireland products, from the European Medicines Agency.

The timing of the product being placed on the market is an issue for the marketing authorisation holder.

### **Changes to authorisations most relevant to vets**

The changes to authorisations most relevant to vets can be found below. Each product is listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics (SPC) sections have been revised/changed.

Changes to the SPC, labels and leaflets may change how the medicines should be used. Details can be found on the VMD's Product Information Database (PID) at [www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed).

Due to ongoing assessments, there may be a delay between the point at which a new change is authorised and the updated SPC being available on the PID. There may also be a delay between the point at which any SPC changes are authorised and implementation in the product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.

## Food producing animals

### **Betamox 150 mg/ml Suspension for Injection (Cats, Cattle, Dogs, Pigs, Sheep)**

Norbrook Laboratories Limited UK POM-V

Section 4.6: Penicillins and cephalosporins may cause hypersensitivity (allergy, allergic skin reactions) after use. Allergic reactions may occasionally be serious (anaphylaxis).

### **Norfenicol 300 mg/ml Solution for Injection for Cattle and Pigs**

Norbrook Laboratories Limited GB & NI POM-V

Section 6.6: The veterinary medicinal product should not enter water courses as florfenicol may be dangerous for fish and other aquatic organisms.

## Companion animals

### **Advantage Chewable Chewable Tablets for Dogs (Range)**

Elanco GmbH GB NFA-VPS

Section 4.6: Additions of bloody diarrhoea, polydipsia, pruritus (itching), inappropriate urination, polyuria (increased urination), and urinary incontinence at a frequency of “very rare” (<1 animal / 10,000 animals treated, including isolated reports).

### **Credelio chewable tablets for dogs (Range)**

Elanco GmbH NI POM-V

Section 3.2: Addition of two new indications:

For the treatment of sarcoptic mange (*Sarcoptes Scabiei*).

By killing the vector *Dermacentor reticulatus*, the veterinary medicinal product reduces the risk of transmission of the vector-borne pathogen *Babesia canis canis*.

### **Credelio Plus Chewable Tablets for Dogs (Range)**

Elanco GmbH NI POM-V

Section 3.2: Addition of two new indications:

For the treatment of sarcoptic mange (*Sarcoptes Scabiei*).

By killing the vector *Dermacentor reticulatus*, the veterinary medicinal product reduces the risk of transmission of the vector-borne pathogen *Babesia canis canis*.

### **Felpreva Spot-on Solution for Cats (Range)**

Vetoquinol SA GB & NI POM-V

Section 3.6: Addition of Application site reaction (e.g. scratching, erythema, hair loss, inflammation) (mild and transient) at a frequency of “rare” (more than 1 but less than 10 animals in 10,000 animals treated).

### **Galastop 50 ug/ml Oral Solution (Dogs)**

Ceva Salute Animale S.p.A UK POM-V

Section 3.6: adverse events updated: anorexia at a frequency of “very common” (more than 1 in 10 animals treated displaying adverse event(s)), vomiting at a frequency of “common”(more than 1 but less than 10 animals in 100 animals treated), and drowsiness,

muscle tremor, ataxia, twitching, trembling, hyperactivity, restlessness, aggression, distress, hyperexcitation, hypotension, and allergic reaction at a frequency of “very rare” (<1 animal / 10,000 animals treated, including isolated reports).

### **Librela Solution for Injection for Dogs (Range)**

Zoetis Belgium NI POM-V

Section 4.6: adverse events updated: diarrhoea and vomiting at a frequency of “rare” (more than 1 but less than 10 animals in 10,000 animals treated) and low amounts of red blood cells (immune-mediated haemolytic anaemia), joint pain, lameness and swelling in multiple joints (immune-mediated polyarthritis), low amounts of platelets (thrombocytes) (immune-mediated thrombocytopenia), weakness, loss of movement, and convulsion at a frequency of “very rare” (<1 animal / 10,000 animals treated, including isolated reports).

### **Lotimax Chewable Tablets for Dogs (Range)**

Elanco GmbH NI POM-V

Section 3.2: Addition of two new indications:

For the treatment of sarcoptic mange (*Sarcoptes Scabiei*).

By killing the vector *Dermacentor reticulatus*, the veterinary medicinal product reduces the risk of transmission of the vector-borne pathogen *Babesia canis canis*.

### **Melosus 0.5 mg/ml Oral Suspension for Cats**

CP Pharma Handelsgesellschaft mbH NI POM-V

Section 4.2: Addition of alleviation of pain and inflammation in acute musculo-skeletal disorders in cats.

### **NexGard Chewable Tablets for Dogs (Range)**

Boehringer Ingelheim Vetmedica GmbH GB POM-V

Section 3.2 Addition of two new indications:

For reduction of the risk of infection with *Babesia canis* via transmission by *Dermacentor reticulatus* for 28 days. The effect is indirect due to the activity of the veterinary medicinal product against the vector.

For reduction of the risk of infection with *Dipylidium caninum* via transmission by *Ctenocephalides felis* for 30 days. The effect is indirect due to the activity of the veterinary medicinal product against the vector.

### **Nobivac L4 Suspension for Injection for Dogs**

MSD Animal Health UK Limited GB POM-V

Section 3.2: Addition of new indications:

Indications against two new *Leptospira* serovars - *Icterohaemorrhagiae* and *Grippotyphosa*  
Indications against existing *Leptospira* serovars *Canicola*, *Copenhageni*, *Banana/Liangguang*, and *Bratislava* and efficacy against serovar *Australis*.

Section 3.6: Addition of injection site swelling up to 6.5 cm on the day of vaccination and elevated temperature  $\leq 1.4$  °C, up to 3 days after vaccination at a frequency of “very common” (more than 1 in 10 animals treated displaying adverse event(s)).

Section 3.8: Addition of a new associated non-mixed use claim with Nobivac Rabies.

For more information, contact the VMD at [postmaster@vmd.gov.uk](mailto:postmaster@vmd.gov.uk)